

Supplemental Table. Schedule of the blood examination. **Bold**, performed in the presence or absence of anti-emicizumab monoclonal antibodies; *, Anti-ADAMTS-13 antibody is also measured when ADAMTS-13 activity is low (< 10%); #, performed with samples obtained only in Nara Medical University.

	Observation time points (month)				Event: BPA infusion at breakthrough bleeds or perioperative management	
	0	12	24	36	Pre BPA	Post BPA
Standard laboratory tests: WBC, RBC, haemoglobin, haematocrit, platelets, AST, ALT, LDH, total bilirubin, indirect bilirubin, BUN, creatinine, fibrinogen, plasminogen, FDP, D-dimer, TAT, PIC	+	+	+	+	+	+
Global assays: TGT, CWA, CFWA						
TMA/TE-related tests: VWF:RCo, VWF:Ag, ADAMTS-13 activity, Anti-ADAMTS-13 antibody*	+	+	+	+	+	+
TMA/TE-related tests: VWF multimer analysis,	-	-	-	-	+	+
Whole blood global assays: ROTEM , T-TAS, platelet aggregometry	-	-	-	-	+ [#]	+ [#]

BPA, bypassing agent; WBC, white blood cells; RBC, red blood cells; AST, aspartate aminotransferase; ALC, alanine aminotransferase; LDH, lactate dehydrogenase; BUN, blood urea nitrogen; FDP, fibrin/fibrinogen degradation product; TAT, thrombin-antithrombin complex; PIC, plasmin-plasmin inhibitor complex; TGT, thrombin generation test; CWA, clot waveform analysis; CFWA, clot-fibrinolysis waveform analysis; TMA, thrombotic microangiopathy; TE, thromboembolism; VWF, von Willebrand factor; RCo, ristocetin cofactor activity; Ag, antigen; ADAMTS-13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; ROTEM, rotational thromboelastometry; T-TAS, total thrombus formation analysis system.